A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use

Infection Control and Hospital Epidemiology

Volumn 26, Issue 3, 2005, Pages 273-280

  Muto, Carlene A ^a,b,e   Pokrywka, Marian ^a   Shutt, Kathleen ^b   Mendelsohn, Aaron B ^c   Nouri, Kathy ^a   Posey, Kathy ^a   Roberts, Terri ^a   Croyle, Karen ^a   Krystofiak, Sharon ^a   Patel Brown, Sujata ^b   Pasculle, A William ^a,d   Paterson, David L ^b   Saul, Melissa ^b   Harrison, Lee H ^b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Univ of Pittsburgh Sch of Medicine ^*

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CLINDAMYCIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; COLON RESECTION; CONTROLLED STUDY; DIARRHEA; EPIDEMIC; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; TEACHING HOSPITAL;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CAUSE OF DEATH; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; DISEASE OUTBREAKS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FLUOROQUINOLONES; HOSPITALS, TEACHING; HUMANS; LOGISTIC MODELS; MALE; OFLOXACIN; PENNSYLVANIA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 20144386999     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502539     Document Type: Article

References (49)

1. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95-100.
2. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573-581.
3. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993;269:71-75.
4. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-210.
5. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97-100.
6. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283-290.
7. Lai K, Melvin ZS, Menard MJ, et al. Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol 1997;18:628-632.
8. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272-277.
9. Drapin MS, Worthington MG, Chang TW, Razvi SA. Clostridium difficile colitis mimicking acute peritonitis. Arch Surg 1985;120:1321-1322.
10. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995;38:350-354.
11. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-353.
12. Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis. Johns Hopkins Med J 1981;149:6-9.
13. Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med 1989;110:255-257.
14. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during hospital outbreak. Infect Control Hosp Epidemiol 1991;12:345-348.
15. Zimmerman RK. Risk factors for Clostridium difficile cytotoxin-positive diarrhea after control for horizontal transmission. Infect Control Hosp Epidemiol 1991;12:96-100.
16. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678-684.
17. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994;89:519-523.
18. Cartmill TD, Panigrahi H, Worsley MA, et al. Management and control of a large outbreak of diarrhea due to Clostridium difficile. J Hosp Infect 1994;27:1-15.
19. Watanakunakorn PW, Watanakunakorn C, Hazy J. Risk factors associated with Clostridium difficile diarrhea in hospitalized adult patients: a case-control study-sucralfate ingestion is not a negative risk factor. Infect Control Hosp Epidemiol 1996;17:232-235.
20. Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22:572-575.
21. Tedesco FJ. Ampicillin-associated diarrhea: a prospective study. American Journal of Digestive Diseases 1975;20:295-297.
22. Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. J Infect Dis 1977;135(suppl):S104-S110.
23. Wiström J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2,462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47:43-50.
24. Crabtree T, Pelletier S, Gleason T, Pruett T, Sawyer R. Clinical characteristics and antibiotic utilization in surgical patients with Clostridium difficile-associated diarrhea. Am Surg 1999;65:507-511.
25. Bauwens JE, McFarland LV, Melcher AS. Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997;31:1090.
26. Low N, Harries A. Ciprofloxacin and pseudomembranous colitis. Lancet 1990;336:1510.
27. Hillman RJ, Gopal R, Harris RJ. Ciprofloxacin as a cause of Clostridium difficile-associated diarrhea in an HIV antibody positive patient. J Infect 1990;21:205-207.
28. Cain DB, O'Conner ME. Pseudomembranous colitis associated with ciprofloxacin. Lancet 1990;336:946.
29. Bates CJ, Wilcox MH, Spencer RC. Ciprofloxacin and Clostridium difficile infection. Lancet 1990;336:1193.
30. Loge RV. Oral fluoroquinolone therapy for Clostridium difficile enterocolitis. JAMA. 1989;261:2063-2064.
31. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-645.
32. McCusker ME, Harris AD, Perencevich E, Roghmann M-C. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730-733.
33. Dallai RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-372.
34. Pokrywka M, Croyle K, Pasculle AW, Muto CA. Clostridium difficile colitis resulting in colectomies: case-control study. Presented at the 11th Annual Meeting of the Society for Healthcare Epidemiology of America; April 1-3, 2001; Toronto, Ontario, Canada.
35. Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17:53-80.
36. Yount RJ, Vries JK, Councill CD. The Medical Archival Retrieval system: an information retrieval system based on distributed parallel processing. Information Processing and Management 1991;27:1-11.
37. World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification Index With Defined Daily Doses (DDDs). Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2000:94-100. Available at www.whocc.no/atcddd.
38. Mundy LS, Shanholtzer CJ, Willard KE, Gerding DE, Peterson LR. Laboratory detection of Clostridium difficile: a comparison of media and incubation systems. Am J Clin Pathol 1995;103:52-56.
39. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, ed. 5. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001. Approved standard. Document M11-A5.
40. Clabots CR, Johnson S, Bettin KM, et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 1993;31:1870-1875.
41. Rothman KJ, Greenland S. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 1998:286, 737.
42. Schlesselman JJ. Basic concepts in the assessment of risk. In: Lilienfeld AM, ed. Case-Control Studies: Design, Conduct, Analysis. New York: Oxford University Press; 1982:27-68.
43. Clabots CR, Peterson LR, Gerding DN. Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing. J Infect Dis 1988;158:731-736.
44. Wilcox MH, Fawley W, Freeman J, Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2000;46:551-556.
45. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004;38:646-648.
46. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:1645-1651.
47. Kristjansson M, Samore MH, Gerding DN, et al. Molecular differentiation of Clostridium difficile: a comparison of restriction endonuclease analyses, ribotyping, and pulsed field gel electrophoresis. J Clin Microbiol 1994;32:1963-1969.
48. Rafferty ME, Baltch AL, Smith RP, et al. Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing Clostridium difficile outbreak. J Clin Microbiol 1998;36:2957-2963.
49. Haassen CHW, van Haren HA, Horrevorts AM. Molecular fingerprinting of Clostridium difficile isolates: pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J Clin Microbiol 2002; 40:101-104.